综述:脂肪性肝病中FIB-4指数的过去、现在与未来
本综述回顾了FIB-4指数在脂肪性肝病中的发展、验证与临床应用。FIB-4最初在HIV/丙肝共感染者中推导,已在SLD人群中验证,对进展期纤维化有中等判别力,双阈值和年龄校正 cutoff 下阴性预测值高。现代诊疗路径将FIB-4作为一线分诊测试,不确定或升高者行瞬时弹性成像等二线检测,专科转诊和选择性肝活检用于诊断不确定或检测不一致。
要点
- FIB-4是SLD一线分诊测试,高阴性预测值有助于排除进展期纤维化。
- FIB-4不应作为药物资格的独立选择工具,需确认性分期识别F2-F3并排除肝硬化。
- 未来方向包括轨迹监测、联合弹性成像和多分析物生物标志物。
核心结论
- FIB-4仍是可扩展的前门测试,但不应作为药物资格的独立选择工具,需确认性分期识别F2-F3疾病并排除肝硬化。
研究设计与样本
- 综述总结了FIB-4在SLD中的过去、现在和未来,涵盖血清纤维化评估的发展、在SLD亚型中的验证、临床路径整合、真实世界性能和精准治疗及纵向风险评估中的潜在作用。
主要发现
- FIB-4最初在HIV/丙肝共感染患者中使用年龄、AST、ALT和血小板计数推导,此后在SLD人群中得到验证。
- FIB-4对进展期纤维化通常提供中等判别力,使用双阈值和年龄校正 cutoff 时阴性预测值高。
关键数值与推荐
- 现代诊疗路径将FIB-4作为一线分诊测试,不确定或升高结果后行瞬时弹性成像或其他二线测试,专科转诊和选择性肝活检保留给诊断不确定或检测不一致者。
临床怎么用
- 临床可将FIB-4用作SLD的一线分诊测试,对不确定或升高者行二线检测,需确认性分期识别F2-F3并排除肝硬化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Steatotic liver disease (SLD) is highly prevalent, and fibrosis stage is the strongest determinant of liver-related outcomes, hepatocellular carcinoma and mortality. Liver biopsy remains the reference standard for staging, but it is invasive, subject to sampling and observer variability. These limitations have accelerated the use of noninvasive tests (NITs) across various settings. AIMS: This review summarizes the past, present and future of the Fibrosis-4 (FIB-4) index in SLD. METHODS: We reviewed the development of serum-based fibrosis assessment, validation of FIB-4 across SLD subtypes, its incorporation into clinical pathways, real-world performance and potential role in precision therapy and longitudinal risk assessment. RESULTS: Initially derived in patients with HIV/hepatitis C coinfection using age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count, FIB-4 has since been validated across SLD populations. FIB-4 generally provides moderate discrimination for advanced fibrosis and high negative predictive value (NPV) when used with dual thresholds and age-adjusted cutoffs. Modern care pathways operationalize FIB-4 as the first-line triage test, followed by transient elastography or another second line test for indeterminate or elevated results, with specialty referral and selective biopsy reserved for diagnostic uncertainty or discordant testing. CONCLUSIONS: In the precision therapy era, FIB-4 remains a scalable front-door test but should not serve as a stand-alone selector for drug eligibility; confirmatory staging is required to identify F2-F3 disease and exclude cirrhosis. Future directions include trajectory-based monitoring, integration with elastography and multi-analyte biomarkers, and selective layering of genetic risk to refine prognosis in intermediate and high-risk strata.
引用
- Soni K, Jahagirdar V, Albhaisi O, et al. Review Article: Fibrosis-4 Index in Steatotic Liver Disease-Past, Present and Future. Aliment Pharmacol Ther. 2026. PMID: 42839344. doi:10.1111/apt.71037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。